Aptamer Group Plc APTA

LSE · United Kingdom · Health Technology

GBp 0.3100-0.01 (-1.59%)

Market closed· Oct 1, 2026, 2:19 PM UTC· GBp · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Aptamer Group Plc APTA

LSE · United Kingdom · Health Technology

GBp 0.3100-0.01 (-1.59%)

Market closed· Oct 1, 2026, 2:19 PM UTC· GBp · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-50.40% · 6MFull-screen chart

Open GBp 0.00High GBp 0.3100Low GBp 0.3100Close GBp 0.3100Volume 38.22K

Oct 1, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: GBp 0.3150
Volume: 38.22K
Market cap: £10.92M
Next earnings date: 2026-10-20
Avg. volume (1Y): 5.91M

Performance

1 week

-3.08%

1 month

-10.00%

3 months

-33.68%

6 months

-47.50%

Year to date

-69.71%

1 year

-56.25%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Biotechnology
Country: United Kingdom
Exchange: LSE
Shares outstanding: 3.47B
ISIN: GB00BNRRP542
Beta: 1.54

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceSep 22, 2026

Secure the Aptamer Market Advantage: Benchmark SomaLogic, Aptamer Group, Base Pair Biotechnologies and NeoVentures as Precision Diagnostics and Therapeutics Reshape Revenue Through the Forecast Period

Aptamers are gaining traction in precision therapies, diagnostics and biosensors, driven by SELEX advances, lower production costs, personalized medicine and targeted drug delivery.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Aptamers - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Aptamers was estimated at US$199.9 Million in 2025 and is projected to reach US$715.6 Million by 2032, growing at a CAGR of 20.0% from 2025 to 2032. This co

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.